NL00150012L7
NL00150012L7
NewAmsterdam Pharma Company N.V
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 2.58B EUR | 3.99B EUR | 3.73B EUR | 4.01B EUR |
Enterprise Value | 1.91B EUR | 3.56B EUR | 3.28B EUR | 3.52B EUR |
Valuation Multiples | ||||
Trailing P/E | -- | -- | -- | -- |
Forward P/E | -14.11x | -- | -- | -- |
Price to Sales | 362.17x | 559.92x | 165.46x | 205.54x |
Price to Book | 4.02x | 6.31x | 5.61x | 5.87x |
EV/Revenue | 267.88x | 500.37x | 145.19x | 180.45x |
EV/EBITDA | -7.81x | -- | -- | -- |
Price to FCF (P/FCF) | -- | -- | -- | -- |
EV/FCF | -- | -- | -- | -- |
FCF Yield | -1.76% | -3.6% | -3.81% | -2.78% |